EFFECT OF AN EXCITATORY AMINO ACID ANTAGONIST (MK-801) ON NEUROLOGIC OUTCOME IN A CANINE MODEL OF COMPLETE CEREBRAL ISCHEMIA

1988 ◽  
Vol 69 (3A) ◽  
pp. A582-A582 ◽  
Author(s):  
W. J. Perkins ◽  
W. L. Lanier ◽  
B. W. Scheithauer ◽  
J. H. Milde
1988 ◽  
Vol 69 (3A) ◽  
pp. A846-A846 ◽  
Author(s):  
W. L. Lanier ◽  
W. J. Perkins ◽  
B. Ruud ◽  
J. H. Milde ◽  
J. D. Michenfelder

1989 ◽  
Vol 481 (2) ◽  
pp. 228-234 ◽  
Author(s):  
John D. Michenfelder ◽  
William L. Lanier ◽  
Bernd W. Scheithauer ◽  
William J. Perkins ◽  
Gary T. Shearman ◽  
...  

1989 ◽  
Vol 9 (6) ◽  
pp. 795-804 ◽  
Author(s):  
Jerry E. Fleischer ◽  
Akio Tateishi ◽  
John C. Drummond ◽  
Mark S. Scheller ◽  
Marjorie R. Grafe ◽  
...  

The excitatory amino antagonist MK-801 was administered to cats following resuscitation from cardiac arrest to evaluate its effect on neurologic and neuropathology outcome in a clinically relevant model of complete cerebral ischemia. In 29 cats studied, cardiac arrest (ventricular fibrillation) was maintained for 18 min and resuscitation was successfully performed in 21 cats. Four animals underwent a sham arrest. MK-801 or placebo was administered in a blinded, randomized manner. Beginning at 5 min post resuscitation (PR), MK-801 330 μg/kg over 2 min followed by 73 μg/kg/h for 10 h or the same volume of placebo was administered. Resuscitated animals remained paralyzed and sedated in an intensive care setting for 24–30 h PR. Neurologic examinations were performed at 2, 4, and 7 days PR by observers blinded to the treatment groups. Seventeen cats were entered into data analysis (nine MK-801-treated and eight placebo-treated). MK-801-treated animals had a significantly greater neurologic deficit score (NDS) rank (0 = normal, 100 = brain death) 2 days PR (mean rank 12.1 vs. 5.6; p = 0.008). This difference is most likely due to ongoing sedative actions of MK-801. There were no significant differences in NDS rank at 4 (10.3, MK-801 vs. 7.5, placebo) and 7 (9.6, MK-801 vs. 8.3, placebo) days PR. There were no significant differences in frontal cortex, hippocampus, occipital cortex, or cerebellar neuropathology between groups. Sham-arrested cats had normal neurologic and neuropathologic evaluations. In the circumstance of complete cerebral ischemia as employed in the current study, MK-801 had no beneficial effect upon neurologic or neuropathologic outcome.


1994 ◽  
Vol 635 (1-2) ◽  
pp. 331-334 ◽  
Author(s):  
Yoichi Katayawa ◽  
Tatsuro Kawata ◽  
Takeshi Maeda ◽  
Koichi Ishikawa ◽  
Takashi Tsubokawa

1991 ◽  
Vol 568 (1-2) ◽  
pp. 294-298 ◽  
Author(s):  
Yoichi Katayama ◽  
Toru Tamura ◽  
Donald P. Becker ◽  
Takashi Tsubokawa

1995 ◽  
Vol 83 (2) ◽  
pp. 325-335. ◽  
Author(s):  
C. Thomas Wass ◽  
William L. Lanier ◽  
Roger E. Hofer ◽  
Bernd W. Scheithauer ◽  
Amy G. Andrews

Background Changes in basal temperature of > or = 1 degree C (e.g., fever-induced hyperthermia or anesthesia-related hypothermia) are a common occurrence in neurologically impaired patients. The current study tested the hypothesis that temperature changes as small as 1 degree C or 2 degrees C would significantly alter post-ischemic functional neurologic outcome and cerebral histopathology. The hypothesis was tested in a canine model of transient, complete cerebral ischemia. Methods After institutional approval, 21 dogs were randomly assigned to one of three temperature-specific groups: (1) a reference group maintained at 37.0 +/- 0.3 degree C (target temperature +/- range); (2) a 38.0 +/- 0.3 degree C group; or (3) a 39.0 +/- 0.3 degree C group (n = 7 per group). Complete cerebral ischemia 12.5 min in duration was produced using an established model of arterial hypotension plus intracranial hypertension. Right atrial and cranial (beneath the temporalis muscles) temperatures were maintained at the target value, beginning 20 min before ischemia and ceasing 1 h postischemia. Thereafter, temperatures were returned to 37.0 +/- 0.3 degree C in all dogs. After discharge from the intensive care environment, all dogs were placed in a temperature-controlled recovery area. Neurologic assessment was performed by a blinded observer at 24, 48, and 72 h postischemia using a 100-point scoring scale. After the 72 h examination (with the dogs anesthetized) or at the time of ischemia-related death, the brains were excised and preserved. The brains subsequently were histologically scored by a neuropathologist who was unaware of the treatment groups. All 21 dogs were included in the analysis of neurologic function; however, only dogs that survived for > or = 24 h postischemia were included in the histopathology analysis. Results Dogs were well matched for systemic physiologic variables throughout the study, with the exception of temperature. During the 72 h postischemic examination, dogs maintained at 37 degrees C were either normal or near normal. In contrast, dogs maintained at 39 degrees C were either comatose or died from ischemia-related causes. Dogs maintained at 38 degrees C were intermediate between 37 degrees C and 39 degrees C dogs. When compared with the reference group, both 38 degrees C and 39 degrees C dogs had significantly worse neurologic function scores (P < 0.01 and < 0.001, respectively) and histopathology scores (P < 0.01 for both). There also was a significant correlation between neurologic function and histopathology rank scores (rs = 0.96; P < 0.001). Conclusions Small, clinically relevant changes in temperature (1 degree C or 2 degrees C) resulted in significant alterations in both postischemic neurologic function and cerebral histopathology. Assuming that our results are transferable to humans, the results suggest that, in patients at imminent risk for ischemic neurologic injury, body temperature should be closely monitored. Further, the clinician should aggressively treat all episodes of hyperthermia until the patient is no longer at risk for ischemic neurologic injury.


1990 ◽  
Vol 10 (2) ◽  
pp. 252-261 ◽  
Author(s):  
William L. Lanier ◽  
William J. Perkins ◽  
Bente R. Karlsson ◽  
James H. Milde ◽  
Bernd W. Scheithauer ◽  
...  

The present study was designed to determine if the noncompetitive excitatory amino acid antagonist, dizocilpine maleate, when administered after a 17 min period of complete cerebral ischemia in primates, would improve postischemic neurologic function and hippocampal histopathologic outcome when compared to placebo-treated animals. Ten pigtail monkeys were anesthetized and subjected to complete cerebral ischemia using an established neck tourniquet model. Five minutes postischemia, five monkeys received dizocilpine 300 μg/kg i.v. over 5 min, followed by an infusion of 150 μg/kg/h for 10 h. This produced plasma levels of the drug in excess of 30 ng/ml for the duration of the infusion. An additional five monkeys were treated with an identical volume of saline placebo. All monkeys received intensive care for the initial 24 to 48 h postischemia. At 96 h postischemia, there was no significant difference in neurologic function between the two groups ( p = 0.53, with the placebo group having the numerically better outcome). There also was no significant difference between hippocampal histopathology scores between dizocilpine and placebo-treated monkeys. The authors conclude that dizocilpine is not an efficacious therapy in the treatment of neurologic injury that occurs following complete cerebral ischemia in this primate model.


1993 ◽  
Vol 79 (2) ◽  
pp. 347-353 ◽  
Author(s):  
Roger E. Hofer ◽  
Thomas J. Christopherson ◽  
Bernd W. Scheithauer ◽  
James H. Milde ◽  
William L. Lanier

Sign in / Sign up

Export Citation Format

Share Document